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Abstract: Anemia is a very common clinical problem in patients with chronic kidney disease 
(CKD) and is associated with increased morbidity and mortality in these patients. Erythropoietin 
is a hormone synthesized in the kidney responsible for red blood cell maturation in the bone 
marrow. It is deﬁ  cient in the majority of patients with advanced kidney disease thereby 
predisposing to anemia. Since the approval of recombinant human erythropoietin (epoetin 
alfa) by the US FDA in 1989, epoetin alfa and similar agents now collectively known as 
erythropoietin stimulating agents (ESA) have become the standard of care for the treatment of 
the erythropoietin-deﬁ  cient anemia that occurs in most patients with CKD. In this review, we 
have outlined the considerations that need to be taken into account when prescribing ESA for 
the treatment of anemia in CKD.
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Introduction
The National Kidney Foundation of The United States of America (Levey et al 2003) 
deﬁ  nes chronic kidney disease (CKD) as (a) evidence of kidney damage based on abnor-
mal urinalysis results (eg, proteinuria, hematuria) or structural abnormalities observed 
on ultrasound images or (b) an absolute glomerular ﬁ  ltration rate (GFR) of less than 
60 mL/min for 3 or more months. Based on this deﬁ  nition, guidelines are developed 
that classify the progression of renal disease into 5 stages, from kidney disease with 
a preserved GFR to end-stage kidney failure. In Stage 1, there is evidence of kidney 
damage but GFR is preserved (>90 mL/min). Stage 2 is mild kidney damage with 
GFR 60–90 mL/min; Stage 3 is moderate kidney damage with GFR 30–59 mL/min; 
Stage 4 is severe kidney damage with GFR 15–29 mL/min while Stage 5 is end stage 
renal disease (ESRD) with GFR <15 mL/min. Patients in Stage 5 are often treated 
with dialysis or kidney transplantation.
CKD is a worldwide public health problem. In the US alone, over 30 million 
people are afﬂ  icted with CKD and the number of patients eventually reaching ESRD 
is projected to rapidly increase from 450,000 in 2003 to 661,330 by the year 2010 
(US RDS 2005). This high prevalence of CKD, the attendant need for anemia treat-
ment with ESA, and the high costs associated with anemia treatment in CKD calls for 
a more structured approach on the use of these agents.
Anemia deﬁ  ned as hemoglobin concentration below 13.0 g/dL for adult males 
and post-menopausal women, and a hemoglobin below 12.0 g/dL for pre-menopausal 
women (World Health Organization 1968), is a major co-morbidity of CKD and is 
common in all stages but becomes more pronounced at the latter stages of kidney 
failure (McClellan et al 2004). Erythropoietin deﬁ  ciency is the most signiﬁ  cant cause 
of anemia in CKD and has been demonstrated to occur at each stage of kidney failure. 
Because the kidney is the sole source of erythropoietin (EPO) synthesis in adults, 
reduction in kidney mass as occurs in progressive CKD often results in impairment of Patient Preference and Adherence 2008:2 196
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EPO production, resulting in anemia. Except for polycystic 
kidney disease, in which EPO production is preserved due 
to the fact that the epithelial cells of the cysts produce large 
amounts of EPO, other causes of kidney failure, including 
diabetes, hypertension, glomerulonephritis, are universally 
associated with anemia, which worsens as kidney failure 
progresses. Although recombinant human erythropoietin is 
a substitute for the deﬁ  ciency observed in CKD, therapy of 
anemia often involves many other issues detailed below that 
need to be considered in order to effectively correct anemia, 
reduce costs and minimize side effects.
Impact of anemia on health
Anemia is a contributing factor in many of the symptoms 
associated with reduced kidney function. These include 
fatigue, depression, reduced exercise tolerance and dyspnea. 
In addition, anemia has direct adverse cardiovascular disease 
(CVD) consequences (McFarlane et al 2006), such as left 
ventricular hypertrophy (LVH) and left ventricular systolic 
dysfunction, coronary artery disease, and stroke (McLellan 
et al 2002; Jurkowitz et al 2003). As a result, patients with 
anemia due to CKD are at increased risk of hospitalization, 
increased hospital length of stay, reduced quality of life and 
mortality (Ma et al 1999; Collins et al 2000).
Types of erythropoietin stimulating 
agents (ESA) used in treating 
anemia in CKD
The first recombinant human erythropoietin (Epogen® 
[epoetin alfa], Amgen) in 1989 (Eschbach et al 1989) signiﬁ  -
cantly improved the clinical management of anemia of CKD, 
primarily in dialysis patients. By 2005, 99% of in-center 
hemodialysis patients received ESA treatment for their ane-
mia, as outlined in Table 1. ESA therapy is the largest single 
Medicare drug expenditure in the US, totaling US$1.8 billion 
in 2004 and comprised 11% of all Medicare ESRD costs 
(Mae et al 2007). In the US, epoetin alfa is also marketed as 
Procrit® (Ortho Biotech) primarily in pre-ESRD patients. In 
Europe epoetin alfa (Eprex®, Ortho Biotech) and epoetin beta 
(Neorecormon®, Roche), different only in glycosylation were 
approved for the treatment of anemia of CKD. The above 
ESA are ﬁ  rst generation and typically have shorter half-lives, 
requiring frequent dosing 1 to 3 times weekly. Darbopoetin 
alfa (Aranesp®, Amgen), considered 2nd generation ESA, 
has been modiﬁ  ed from EPO to give it a longer half life and 
typically can be administered once weekly or once every two 
weeks. Recently, a third generation ESA that is modiﬁ  ed from 
EPO by insertion of a large pegylation chain to make it longer 
acting, called continuous EPO receptor activator (Cera®) has 
been approved for marketing as Mircera® (Roche). The action 
of Mircera® on the EPO receptor is different from the other 
ESA, giving it a much longer half life and typically can be 
administered once every two weeks or once every month 
(Macdougall 2008). Irrespective of the type of ESA used, 
the common goal is to correct anemia to target levels. The 
choice of ESA depends on geographic, economics, industry 
pressure, and local policies.
Considerations in the use 
of ESA in CKD
Etiology of anemia
Erythropoietin deﬁ  ciency
As shown in Table 2, EPO deﬁ  ciency is by far the leading cause 
of anemia in patients with CKD. The kidney is the primary site 
of erythropoietin production in adults (Ratcliffe et al 1995). 
Studies utilizing transgenic mice suggest that a population 
of interstitial ﬁ  broblasts (also known as the type I interstitial 
cell) are the major source of renal erythropoietin synthesis 
(Maxwell et al 1993). Deﬁ  ciency of EPO, as occurs in patients 
with CKD, retards maturation of red blood cells from pro-
genitor cells into normoblasts and reticulocytes. Furthermore, 
deﬁ  ciency of EPO decreases the survival of these immature red 
blood cells, a process known as neocytolysis, thereby resulting 
in anemia (Righetti et al 2004). Therefore EPO supplementa-
tion is indicated in patients with CKD who manifest anemia. 
In the absence of other causes, anemia due to EPO deﬁ  ciency 
is often normocytic and normochromic, implying a reduction 
in number but not quality of these cells. Because of the strong 
Table 1 Currently available erythropoietin stimulating agents
Agent Biotech company Main market
First generation ESA
 Epoetin  alfa  (Epogen) Amgen US
  Epoetin alfa (Procrit) Ortho Biotech US
 Epoetin  alfa  (Eprex) Janssen-Ortho Worldwide 
except US
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association between CKD and EPO deﬁ  ciency, it is often 
not necessary to measure serum erythropoietin levels prior 
to treating anemia in these patients. In the presence of other 
causes of anemia detailed below, therapy with recombinant 
erythropoietin alone may not necessarily correct anemia, a 
process known as erythropoietin resistance.
Iron deﬁ  ciency
Iron deﬁ  ciency is prevalent in CKD and dialysis patients. 
Iron deﬁ  ciency may result from nutritional deﬁ  ciency as 
well as blood losses from occult gastrointestinal hemorrhage, 
menstruation, and blood draws. Blood draws are particularly 
signiﬁ  cant in hemodialysis patients in whom up to 2 g of 
iron can be lost per year (KDOQI 2006). Furthermore, EPO 
therapy is associated with increased iron utilization, further 
leading to iron deﬁ  ciency. Thus, iron deﬁ  ciency will develop 
in virtually all dialysis patients receiving EPO unless supple-
mental iron therapy is given intravenously. In fact aggressive 
diagnosis and therapy of iron deﬁ  ciency is the singular cost 
effective strategy in reducing ESA requirements in CKD 
patients (Fishbane et al 1995).
Evaluation of iron stores should include red blood cell 
indices, reticulocyte count, serum iron, total iron binding 
capacity, percentage transferrin saturation, serum ferritin, 
and testing for occult blood in stool. Other less commonly 
used indices of iron deﬁ  ciency include reticulocyte Hb 
Content (CHr) <29 pg and percentage of hypochromic red 
cells (PHRC) <10%. In patients with CKD, absolute iron 
deﬁ  ciency is deﬁ  ned as serum ferritin <100 (<200 for hemodi-
alysis patients) ng/mL and or a transferrin saturation <20%. In 
contrast, some patients often manifest ‘functional’ or ‘relative 
iron deﬁ  ciency’ in which demand for iron in erythropoiesis 
exceeds supply with the administration of ESA. Iron stores 
are adequate in functional iron deﬁ  ciency; however, there is 
an inability to adequately mobilize it from the reticuloendo-
thelial system (RES) to support erythropoiesis. Patients with 
functional iron deﬁ  ciency anemia often respond to intrave-
nous iron (Coyne et al 2007) as opposed to a condition termed 
reticuloendothelial blockade, an extreme case of functional 
iron deﬁ  ciency usually occurring in the setting of acute or 
chronic inﬂ  ammation/infection. This often correlates with 
a high CRP level and/or a high erythrocyte sedimentation 
rate. Typically the serum ferritin level is >200 ng/mL but 
the transferrin saturation <20% in both conditions. Hepci-
din, a peptide produced by the liver, inhibits intestinal iron 
absorption and the release of iron from the RES to circulating 
transferrin. Serum levels of hepcidin are increased in the set-
ting of inﬂ  ammation/infection, and help explain the phenom-
enon of RES blockade in which stored iron is not released to 
circulating transferrin, resulting in a high serum ferritin and 
low transferring saturation level (Wish 2006). Both func-
tional iron deﬁ  ciency and reticuloendothelial blockade may 
lead to EPO resistance (Tonelli et al 2001; Brugnara 2003). 
Serum ferritin and transferrin saturation should be measured 
before initiating ESA therapy and every 1–3 months during 
therapy. Patients with stable hemoglobin in the target range 
who are receiving a stable dose of an ESA should have their 
hemoglobin checked monthly and any evidence of iron deﬁ  -
ciency should be treated with parenteral iron as this route of 
administration is more effective.
Secondary hyperparathyroidism
Secondary hyperparathyroidism parallels CKD and worsens 
with its severity. This is due primarily to deﬁ  ciency in 
1–25 vitD3 and elevated serum inorganic phosphate level 
both of which stimulate parathyroid hyperplasia and 
increased parathyroid hormone synthesis, a process called 
secondary hyperparathyroidism. Secondary hyperparathy-
roidism increases bone turnover, leading to development 
of bone cysts and marrow ﬁ  brosis, impairing bone marrow 
function and subsequently anemia (Barany and Muller 2007). 
Secondary hyperparathyroidism, if uncontrolled, can lead to 
erythropoietin resistance. Therefore secondary hyperparathy-
roidism must be routinely checked and aggressively treated 
in CKD patients.
Chronic inﬂ  ammation
Chronic inﬂ  ammation is an important cause of EPO resis-
tance in CKD patients. Chronic inﬂ  ammation resulting from 
Table 2 Considerations in the use of erythropoietin stimulating 
agents in chronic kidney disease
1. Etiology of anemia
  Erythropoietin  deﬁ  ciency
  Iron  deﬁ  ciency
  Hyperparathyroidism
  Chronic  inﬂ  ammation
    Angiotensin converting enzyme inhibitors
    Pure red cell aplasia
  Malignancy
    B12 and folate deﬁ  ciency
    Hemoglobinopathies, eg, sickle cell anemia
  Hemolytic  anemia
  Malnutrition
2. Target hemoglobin
  Cardiovascular  disease  risk
3. Route of administration
4. HypertensionPatient Preference and Adherence 2008:2 198
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rheumatologic diseases (such as arthritis, lupus), chronic 
infections (such as hepatitis C, soft tissue and bone infec-
tions), and failed renal transplants is associated with increased 
circulating levels of cytokines including CRP, tumor necrosis 
factor, interferon gama, and interleukins (Tsirpanlis et al 
2004), which impair the erythropoietic response to various 
stimuli. As CRP has emerged as the most quantiﬁ  able marker 
of inﬂ  ammation, it should be routinely investigated when 
erythropoietin resistance is suspected and no other cause can 
be identiﬁ  ed. In general, levels of CRP >10 mg/L (Ortega 
et al 2002), suggest signiﬁ  cant inﬂ  ammation. Occasionally 
doubling the erythropoietin dose may overcome the resis-
tance. If no improvement is achieved with doubling the dose, 
further increments are not likely to yield signiﬁ  cant results. 
In such instances, the erythropoietin doses should not be 
stopped as this may precipitate neocytolysis, resulting in 
precipitous decline in red cell count.
Diagnosis of the underlying cause of inﬂ  ammation is key 
in order to eliminate the cause of elevated CRP. If infection 
is diagnosed speciﬁ  c antibiotic therapy or surgical interven-
tion can improve EPO resistance. Similarly, detection and 
treatment of recurrent vasculitis or malignancy may also have 
a high impact. If no cause of high CRP is detected a clotted 
arteriovenous graft should be removed, when appropriate. 
On rare occasions, if the screen for sepsis is negative and 
the patient is believed to have a non-infective inﬂ  ammatory 
condition, administration of steroids might be considered 
(Wanner et al 2007). Alternatively, such patients should be 
maintained on regular doses of erythropoietin and periodic 
red blood cell transfusion.
Pure red cell aplasia
Although rare, administration of ESA may result in forma-
tion of anti-erythropoietin antibodies, thereby leading to pure 
red cell aplasia and erythropoietin resistance (Pollocke et al 
2008). In patients in whom ESA doses have been maximized 
without effect and no other causes can be identiﬁ  ed, serum 
anti-erythropoietin levels and bone marrow biopsy should 
be performed. If conﬁ  rmed, erythropoietin administration 
should be ceased and the patient treated with periodic blood 
transfusions.
Angiotensin converting enzyme inhibitors 
and receptor blockers
Angiotensin converting enzyme inhibitors (ACEI) and 
angiotensin receptor blockers (ARB) can contribute to ane-
mia in CKD patients. The observation that ACEI and ARB 
are preferred drugs in treating post-transplant erythrocytosis 
support the impact of these agents on anemia. Furthermore, 
evidence suggests that dialysis patients treated with ACEI 
and ARB have slightly lower hematocrits than those not on 
these agents. A circulating natural inhibitor of bone marrow 
(N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) has been 
implicated in the pathogenesis of ACEI-induced anemia. The 
ACE enzyme is responsible for the degradation of AcSDKP, 
thus blockade of ACE with ACEI leads to increased circulat-
ing levels of AcSDKP and therefore bone marrow inhibition 
(Le Meur et al 2001). Secondly, erythroid progenitor cell 
lines can be stimulated via angiotensin type II receptors 
therefore blockade of these receptors by ARB may inhibit 
differentiation of erythroid cell lines (Mohanram et al 2008). 
In most instances increase in dose of erythropoietin may 
overcome the resistance induced by ACEI or ARB. If nec-
essary, modest reduction of doses of ACEI or ARB may be 
needed in CKD patients with unexplained anemia. Because 
of the overall cardiovascular beneﬁ  t, in the absence of serious 
complications, complete cessation of ACEI and ARB for the 
purpose of treating anemia is not indicated.
Hemolytic anemia
Hemolytic anemia is associated with various conditions in 
CKD patients including systemic lupus erythematosus and 
microangiopathic hemolytic anemia. Tests of hemolysis such 
as total bilirubin, lactate dehyrogenase, urine hemosiderin, 
urine hemoglobin, haptoglobin, and a peripheral smear 
should be performed to diagnose the presence of hemolysis. 
By far, haptoglobin is the most speciﬁ  c of these tests and a 
depressed value indicates signiﬁ  cant hemolysis. Conﬁ  rma-
tion of immune hemolytic anemia by the above tests requires 
complete hematologic evaluation and possible immunosup-
pressive therapy that is beyond the scope of this article.
Other causes of anemia
As shown in Table 2, other rare causes of anemia in CKD 
patients include folate and B12 deﬁ  ciency, hemoglobinopa-
thies, malignancy, and malnutrition. These causes should be 
routinely investigated and treated.
Target hemoglobin levels
Although the National Kidney Foundation of USA Kidney 
and Dialysis Outcomes and Quality Initiative (K/DOQI) 
guidelines on anemia suggested a hemoglobin target range 
of 11–12 g/dL rather than full normalization, investigators 
have questioned whether normalizing hemoglobin may 
lead to additional beneﬁ  ts (Foley 2006). Two large recent 
randomized controlled trials; Correction of Hemoglobin Patient Preference and Adherence 2008:2 199
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and Outcomes in Renal Insufﬁ  ciency (CHOIR) (Singh et al 
2006) and Cardiovascular Risk Reduction by Early Anemia 
Treatment with Epoetin (CREATE) (Drueke et al 2006) dem-
onstrated increased cardiovascular events and progression to 
dialysis in patients assigned to the highest hemoglobin targets 
(>13.0 g/dL), compared with <12 g/dL. This prompted new 
guidelines published by KDOQI in August 2007 recommend-
ing a hemoglobin target range of 11–12 g/dL for patients with 
CKD (KDOQI 2007). Subsequently the US Food and Drug 
Administration (FDA) issued an advisory (Public Health 
Advisory; Information for Healthcare Professionals) recom-
mending hemoglobin within the range of 10–12 g/dL, with 
more frequent hemoglobin monitoring (twice weekly), so that 
early adjustment to ESA therapy may be instituted to avert 
signiﬁ  cant over treatment. Furthermore, ESA therapy with 
target hemoglobin above 13.0 g/dL has been associated with 
increased progression of many different types of cancers. The 
FDA has warned that ESA should be administered only to 
avoid red blood cell transfusions in cancer patients as they 
do not improve the outcome of cancer treatment and do not 
alleviate fatigue or increase energy in these patients.
Whether the increase risk of cardiovascular events, pro-
gression to dialysis and cancer progression is due to higher 
doses of ESA required to achieve those targets, or is due to 
the increase in hemoglobin per se or a combination of both 
factors is still a subject of debate. Nonetheless, these potential 
complications are important considerations when prescribing 
ESA. In patients with history of cardiovascular disease or 
cancer, strict adherence to the recommended targets should 
be the goal.
Route of administration
The route of administration should be taken into account 
when administering ESA in CKD. Evidence suggests that 
the subcutaneous route usually results in less frequent 
injections, reduces ESA requirement and is cost effective 
than the intravenous route (Tonelli et al 2003). Despite 
this fact, many dialysis patients and perhaps nephrology 
professional staff use the intravenous route since ESA can 
be conveniently administered during the process of dialysis. 
For instance, in the USA, most patients on dialysis receive 
ESA therapy intravenously. In peritoneal dialysis patients 
and in the non-dialysis CKD population the choice is how-
ever limited to subcutaneous administration since patients 
often are instructed to inject themselves at home without 
supervision using the least invasive method, which is sub-
cutaneous. In a few patients who do not exhibit adequate 
response to intravenous ESA administration despite dose 
adjustment, consideration should be given to switching to 
the subcutaneous route. When this switch is considered, the 
subcutaneous dose should be reduced by 30% to avoid the 
possibility of a sudden rise in hemoglobin above target.
Uncontrolled hypertension
Administration of ESA may be associated with exacerbation 
of hypertension in about 5% of patients that will require 
dose adjustment or switching to a different ESA. In the era 
of new and effective antihypertensive therapy, rarely does 
full cessation of ESA become necessary. The mechanism 
of ESA induced hypertension is thought to be related to 
stimulation of the vascular endothelium by ESA resulting 
in increased circulating levels of endothelin. Furthermore 
the increase in hemoglobin associated with ESA therapy 
may increase blood viscosity resulting in vasospasm. As such 
routine monitoring of blood pressure is essential in patients 
treated with ESA (Public Health Advisory; Information for 
Healthcare Professionals).
Conclusion
Treatment of anemia with ESA in patients with CKD is 
indicated to improve quality of life and decrease morbidity 
and mortality. A variety of issues raised in this article need 
to be taken into account when prescribing ESA to treat 
anemia in CKD. Furthermore as emerging data suggests 
that ESA therapy may not be that benign, it is imperative to 
adhere to strict guidelines and keep hemoglobin levels on 
the recommended targets ranges. Such action can only be 
achieved by frequent monitoring of the patient to improve 
overall outcomes.
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